Quiz: What Percentage of Ovarian Cancer Patients Have Metastatic Disease at Diagnosis?

Quiz: What Percentage of Ovarian Cancer Patients Have Metastatic Disease at Diagnosis?

November 1, 2017

Do you know the 5-year overall survival rate for women with ovarian cancer? How about the response rate for platinum-based chemotherapy in newly diagnosed patients? Test your knowledge on these topics and more in our latest quiz.

Do you know the 5-year overall survival rate for women with ovarian cancer? How about the response rate for platinum-based chemotherapy in newly diagnosed patients? Test your knowledge on these topics and more in our latest quiz.

Question 1

Answer

D.60%. According to SEER Program data, 15% of women have localized disease at the time of their ovarian cancer diagnosis, and 20% have regional disease.

Question 2

Answer

D. High-grade serous carcinoma. Women with germline mutations in BRCA1, BRCA2, or both (BRCA1/2) have an increased risk of ovarian cancer, particularly the most common type, invasive high-grade serous carcinoma. In up to 50% of patients with high-grade serous tumors, the tumor cells may be deficient in homologous recombination as a result of germline or somatically acquired BRCA1/2 mutations, epigenetic inactivation of BRCA1, or defects in the homologous recombination pathway that are independent of BRCA1/2.

Question 3

Answer

C.46.5%. According to SEER Program data, the 5-year overall survival rate is 92.5% for women with localized ovarian cancer, 73% for regional disease, and 28.9% for those with distant spread.

Question 4

Answer

A. 19.1 vs 5.5 months. The phase III SOLO-2 trial demonstrated a statistically significant improvement in investigator-assessed progression-free survival in patients randomized to olaparib compared with those who received placebo, with a hazard ratio of 0.30 (95% CI, 0.22–0.41; P < .0001). The estimated median progression-free survival was 19.1 and 5.5 months in the olaparib and placebo arms, respectively.

Question 5

Answer

E. 80%. Ovarian cancer is the leading cause of death from gynecologic tumors in the Western world. Approximately 80% of patients with newly diagnosed ovarian cancer have a response to platinum-based chemotherapy.